Abstract

IMMUNOTHERAPEUTIC MONOCLONAL ANTIBODIES: A GROUNDBREAKING TARGETED THERAPY FOR ORAL CANCER

*Dr. Vijaya Patil, Yatish Chauhan, Rohit Bele and Mahesh Chavan

ABSTRACT

Oral cancer is a devastating disease with limited treatment options and poor outcomes. Monoclonal antibodies (mAbs) offer a promising targeted approach to improve treatment. This review discusses the current state of mAb therapy for oral cancer, including their mechanisms, clinical applications, and potential benefits. mAbs targeting proteins like EGFR, VEGF, PD-1 and PD-L1 have shown encouraging results in preclinical and clinical trials. These mAbs demonstrate improved treatment outcomes and enhanced survival for oral cancer patients. However, challenges remain in optimizing mAb therapy, such as developing effective combination regimens, identifying predictive biomarkers, and implementing personalized treatment approaches. As research progresses, mAbs are poised to revolutionize oral cancer treatment. By offering a targeted, effective therapeutic option, mAbs provide new hope for patients with thisdevastating disease. With further development and optimization,mAb therapy may emerge as a critical component of the treatment arsenal against oral cancer.

Keywords: Immunotherapy, Monoclonal antibody, Targeted therapy, oral cancer.